TELA Bio Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $79.9M+15.3% YoYTTM through 30 Jun 2026
Net Income -$41.2MTTM through 30 Jun 2026
Free Cash Flow -$31.6MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 65.7% |
| EBITDA Margin | -41.7% |
| Operating Margin | -55.0% |
| Net Margin | -51.5% |
Returns
259.5%ROE
-68.9%ROA
Balance Sheet Health
Debt / Equity-10.74x
Current Ratio3.61x
Net Debt$16.4M
Cash & Equivalents$30.4M
Quality Metrics
Altman Z-Score-9.18
Piotroski F-Score3 / 9
FCF Margin-39.6%
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2025: $80.3M
Diluted EPS-$0.77TTMFY2025: $-0.83
Dividend
No dividend
Capital Allocation
R&D Spend$9.5M
Capex Intensity0.6%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.